HuGE Literature Finder
|
||
Records 1-100
|
High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
Neuropathology : official journal of the Japanese Society of Neuropathology 2019 Apr 39 (2): 78-84. Rao Shilpa, Kanuri Nandaki N, Nimbalkar Vidya, Arivazhagan Arimappamagan, Santosh Va |
|
Prognostic Role of Chicken Ovalbumin Upstream Promoter Transcription Factor II in Isocitrate Dehydrogenase-Mutant Glioma with 1p19q Co-Deletion.
Journal of molecular neuroscience : MN 2019 Mar . Chai Yi, Liu Wei, Wang Caixia, Rao Minchao, Zhang Yu |
|
The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
Brain pathology (Zurich, Switzerland) 2019 Jan 29 (1): 85-96. Phillips Joanna J, Gong Henry, Chen Katharine, Joseph Nancy M, van Ziffle Jessica, Bastian Boris C, Grenert James P, Kline Cassie N, Mueller Sabine, Banerjee Anuradha, Nicolaides Theodore, Gupta Nalin, Berger Mitchel S, Lee Han S, Pekmezci Melike, Tihan Tarik, Bollen Andrew W, Perry Arie, Shieh Joseph T C, Solomon David |
|
BRAF V600E, TERT, and IDH2 mutations in pleomorphic xanthoastrocytoma: Observations from a large case-series study.
World neurosurgery 2018 Sep . Ma Chengxin, Feng Rui, Chen Hong, Farrukh Hameed N U, Aibaidula Abudumijit, Song Yanyan, Wu Jinso |
|
Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
Human pathology 2018 Aug 78 138-143. Toth Laura N, de Abreu Francine B, Tafe Laura |
|
Use of metformin and survival of patients with high-grade glioma.
International journal of cancer 2018 Aug . Seliger Corinna, Luber Christian, Gerken Michael, Schaertl Julia, Proescholdt Martin, Riemenschneider Markus J, Meier Christoph R, Bogdahn Ulrich, Leitzmann Michael F, Klinkhammer-Schalke Monika, Hau Pet |
|
IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Cancer science 2018 May . Otani Ryohei, Uzuka Takeo, Higuchi Fumi, Matsuda Hadzki, Nomura Masashi, Tanaka Shota, Mukasa Akitake, Ichimura Koichi, Kim Phyo, Ueki Keisu |
|
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Pathology, research and practice 2018 Apr . Kim Hyun Sik, Kwon Mi Jung, Song Joon Ho, Kim Eun Soo, Kim Ho Young, Min Kyueng-Wh |
|
Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Journal of neuro-oncology 2018 Feb . Mistry Akshitkumar M, Vnencak-Jones Cindy L, Mobley Bret |
|
Association between IDH1/2 mutation and preoperative seizures in patients with low-grade versus high-grade glioma: a systematic review and meta-analysis.
World neurosurgery 2017 Dec . Phan Kevin, Ng Wyatt, Lu Victor M, McDonald Kerrie L, Fairhall Jacob, Reddy Rajesh, Wilson Pet |
|
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Critical reviews in oncology/hematology 2017 Dec 120 1-9. Vuong Huy Gia, Altibi Ahmed M A, Duong Uyen N P, Ngo Hanh T T, Pham Thong Quang, Chan Aden Ka-Yin, Park Chul-Kee, Fung Kar-Ming, Hassell Lew |
|
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Clinical neurology and neurosurgery 2016 Oct 151 31-36. Li Hailong, Li Jiye, Cheng Gang, Zhang Jianning, Li Xuezh |
|
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Oncotarget 2016 Sep . Roodakker Kenney R, Elsir Tamador, Edqvist Per-Henrik D, Hägerstrand Daniel, Carlson Joseph, Lysiak Malgorzata, Henriksson Roger, Pontén Fredrik, Rosell Johan, Söderkvist Peter, Stupp Roger, Tchougounova Elena, Nistér Monica, Malmström Annika, Smits An |
|
GBM-associated mutations and altered protein expression are more common in young patients.
Oncotarget 2016 Aug . Ferguson Sherise D, Xiu Joanne, Weathers Shiao-Pei, Zhou Shouhao, Kesari Santosh, Weiss Stephanie E, Verhaak Roeland G, Hohl Raymond J, Barger Geoffrey R, Reddy Sandeep K, Heimberger Amy |
|
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Neuro-oncology 2016 Aug . Nguyen HuyTram N, Lie Amy, Li Tie, Chowdhury Reshmi, Liu Fei, Ozer Byram, Wei Bowen, Green Richard M, Ellingson Benjamin M, Wang He-Jing, Elashoff Robert, Liau Linda M, Yong William H, Nghiemphu Phioanh L, Cloughesy Timothy, Lai Albe |
|
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Turkish neurosurgery 2016 Aug . Hacisalihoglu Payam, Kucukodaci Zafer, Gundogdu Gokcen, Bilgic Bil |
|
An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016 Jul . Yang Yuan, Mao Qing, Wang Xiang, Liu Yanhui, Mao Yunhe, Zhou Qiao, Luo Jiew |
|
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
Oncotarget 2016 Jul . Schiffgens Salveena, Wilkens Ludwig, Brandes Alba A, Meier Tatiana, Franceschi Enrico, Ermani Mario, Hartmann Christian, Sandalcioglu I Erol, Dumitru Claudia |
|
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Neuro-oncology 2016 Jun . Zhang Biqi, Chang Ken, Ramkissoon Shakti, Tanguturi Shyam, Bi Wenya Linda, Reardon David A, Ligon Keith L, Alexander Brian M, Wen Patrick Y, Huang Raymond |
|
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Medicine 2016 Mar 95 (9): e2583. Chen Jun-Rui, Yao Yu, Xu Hong-Zhi, Qin Zhi-Yo |
|
IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
Journal of neuro-oncology 2016 Jan . Leu Severina, von Felten Stefanie, Frank Stephan, Boulay Jean-Louis, Mariani Lui |
|
Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Journal of clinical pathology 2016 Jan . Rajmohan K S, Sugur Harsha S, Shwetha S D, Ramesh Arvind, Thennarasu Kandavel, Pandey Paritosh, Arivazhagan Arimappamagan, Santosh Va |
|
ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Acta neuropathologica communications 2016 4 (1): 60. Ebrahimi Azadeh, Skardelly Marco, Bonzheim Irina, Ott Ines, Mühleisen Helmut, Eckert Franziska, Tabatabai Ghazaleh, Schittenhelm Je |
|
Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene.
Genes, chromosomes & cancer 2015 Nov 54 (11): 655-67. Lhotska Halka, Zemanova Zuzana, Cechova Hana, Ransdorfova Sarka, Lizcova Libuse, Kramar Filip, Krejcik Zdenek, Svobodova Karla, Bystricka Dagmar, Hrabal Petr, Dohnalova Alena, Michalova Ky |
|
TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Oncotarget 2015 Nov . Gao Ke, Li Gang, Qu Yiping, Wang Maode, Cui Bo, Ji Meiju, Shi Bingyin, Hou Pe |
|
TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Journal of neuro-oncology 2015 Nov . Nencha Umberto, Rahimian Amithys, Giry Marine, Sechi Andrea, Mokhtari Karima, Polivka Marc, Schmitt Yohann, Di Stefano Anna-Luisa, Alentorn Agusti, Labussière Marianne, Sanson Ma |
|
Biomarker-based prognostic stratification of young adult glioblastoma.
Oncotarget 2015 Oct . Zhang Rui-Qi, Shi Zhifeng, Chen Hong, Chung Nellie Yuk-Fei, Yin Zi, Li Kay Ka-Wai, Chan Danny Tat-Ming, Poon Wai Sang, Wu Jinsong, Zhou Liangfu, Chan Aden Ka-Yin, Mao Ying, Ng Ho-Keu |
|
Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.
Human pathology 2015 Sep 46 (9): 1323-30. Vizcaíno M Adelita, Shah Smit, Eberhart Charles G, Rodriguez Fausto |
|
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Neuro-oncology 2015 Sep . Dubbink Hendrikus J, Atmodimedjo Peggy N, Kros Johan M, French Pim J, Sanson Marc, Idbaih Ahmed, Wesseling Pieter, Enting Roelien, Spliet Wim, Tijssen Cees, Dinjens Winand N M, Gorlia Thierry, van den Bent Martin |
|
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Neuro-oncology 2015 Sep 17 (9): 1231-40. Spiegl-Kreinecker Sabine, Lötsch Daniela, Ghanim Bahil, Pirker Christine, Mohr Thomas, Laaber Magdalena, Weis Serge, Olschowski Alfred, Webersinke Gerald, Pichler Josef, Berger Walt |
|
Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Neuropathology : official journal of the Japanese Society of Neuropathology 2015 Aug 35 (4): 324-35. Ogura Ryosuke, Tsukamoto Yoshihiro, Natsumeda Manabu, Isogawa Mizuho, Aoki Hiroshi, Kobayashi Tsutomu, Yoshida Seiichi, Okamoto Kouichiro, Takahashi Hitoshi, Fujii Yukihiko, Kakita Akiyos |
|
Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
AJNR. American journal of neuroradiology 2015 Aug . Wang Y Y, Wang K, Li S W, Wang J F, Ma J, Jiang T, Dai J |
|
TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Oncotarget 2015 Jul . Zhang Zhen-Yu, Chan Aden Ka-Yin, Ding Xiao-Jie, Qin Zhi-Yong, Hong Christopher S, Chen Ling-Chao, Zhang Xin, Zhao Fang-Ping, Wang Yin, Wang Yang, Zhou Liang-Fu, Zhuang Zhengping, Ng Ho-Keung, Yan Hai, Yao Yu, Mao Yi |
|
The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Human pathology 2015 Jul . Feng Jie, Hao Shuyu, Pan Changcun, Wang Yu, Wu Zhen, Zhang Junting, Yan Hai, Zhang Liwei, Wan Ho |
|
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
Acta neuropathologica 2015 May 129 (5): 669-78. Korshunov Andrey, Ryzhova Marina, Hovestadt Volker, Bender Sebastian, Sturm Dominik, Capper David, Meyer Jochen, Schrimpf Daniel, Kool Marcel, Northcott Paul A, Zheludkova Olga, Milde Till, Witt Olaf, Kulozik Andreas E, Reifenberger Guido, Jabado Nada, Perry Arie, Lichter Peter, von Deimling Andreas, Pfister Stefan M, Jones David T |
|
Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas.
Brain tumor pathology 2015 Apr 32 (2): 99-104. Sonoda Yukihiko, Shibahara Ichiyoo, Kawaguchi Tomohiro, Saito Ryuta, Kanamori Masayuki, Watanabe Mika, Suzuki Hiroyoshi, Kumabe Toshihiro, Tominaga Tei |
|
CXCR7 and CXCR4 Expressions in Infiltrative Astrocytomas and Their Interactions with HIF1? Expression and IDH1 Mutation.
Pathology oncology research : POR 2015 Apr 21 (2): 229-40. Bianco Andre Macedo, Uno Miyuki, Oba-Shinjo Sueli Mieko, Clara Carlos Afonso, de Almeida Galatro Thais Fernanda, Rosemberg Sergio, Teixeira Manoel Jacobsen, Nagahashi Marie Suely Kaz |
|
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Acta neuropathologica 2015 Apr 129 (4): 585-96. Olar Adriana, Wani Khalida M, Alfaro-Munoz Kristin D, Heathcock Lindsey E, van Thuijl Hinke F, Gilbert Mark R, Armstrong Terri S, Sulman Erik P, Cahill Daniel P, Vera-Bolanos Elizabeth, Yuan Ying, Reijneveld Jaap C, Ylstra Bauke, Wesseling Pieter, Aldape Kenneth |
|
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Oncotarget 2015 Apr 6 (12): 10617-33. Heidenreich Barbara, Rachakonda P Sivaramakrishna, Hosen Ismail, Volz Florian, Hemminki Kari, Weyerbrock Astrid, Kumar Raj |
|
Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
Oncotarget 2015 Mar 6 (9): 7318-24. Li Rui, Li Hailin, Yan Wei, Yang Pei, Bao Zhaoshi, Zhang Chuanbao, Jiang Tao, You Yongpi |
|
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2015 Feb 22 (2): 348-54. Wang Y, Zhang T, Li S, Fan X, Ma J, Wang L, Jiang |
|
Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
Molecular neurobiology 2015 Feb . Dai Yuting, Ning Xianbin, Han Guoqian, Li W |
|
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 Feb 28 (2): 177-86. Chan Aden Ka-Yin, Yao Yu, Zhang Zhenyu, Chung Nellie Yuk-Fei, Liu Joseph Shu-Ming, Li Kay Ka-Wai, Shi Zhifeng, Chan Danny Tat-Ming, Poon Wai Sang, Zhou Liangfu, Ng Ho-Keu |
|
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Acta neuropathologica 2015 Jan 129 (1): 133-46. Reuss David E, Sahm Felix, Schrimpf Daniel, Wiestler Benedikt, Capper David, Koelsche Christian, Schweizer Leonille, Korshunov Andrey, Jones David T W, Hovestadt Volker, Mittelbronn Michel, Schittenhelm Jens, Herold-Mende Christel, Unterberg Andreas, Platten Michael, Weller Michael, Wick Wolfgang, Pfister Stefan M, von Deimling Andre |
|
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.
Journal of neuro-oncology 2015 Jan 121 (1): 141-50. Lee Seunghyun, Choi Seung Hong, Ryoo Inseon, Yoon Tae Jin, Kim Tae Min, Lee Se-Hoon, Park Chul-Kee, Kim Ji-Hoon, Sohn Chul-Ho, Park Sung-Hye, Kim Il H |
|
IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Gene 2015 Jan 554 (1): 81-6. Kalkan Rasime, Atli Emine ?kbal, Özdemir Muhsin, Çiftçi Evrim, Aydin Hasan Emre, Artan Sevilhan, Arslanta? A |
|
IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
Epilepsy research 2015 Jan 109 100-5. Zhong Zhang, Wang Zheng, Wang Yinyan, You Gan, Jiang T |
|
Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
Asian Pacific journal of cancer prevention : APJCP 2015 16 (8): 3355-60. Kang Xing, Chen Rong, Zhang Jie, Li Gang, Dai Peng-Gao, Chen Chao, Wang Hui-Ju |
|
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
Scientific reports 2015 5 16238. Kickingereder Philipp, Sahm Felix, Radbruch Alexander, Wick Wolfgang, Heiland Sabine, Deimling Andreas von, Bendszus Martin, Wiestler Benedi |
|
PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
PloS one 2015 10 (11): e0142750. Nakae Shunsuke, Sasaki Hikaru, Hayashi Saeko, Hattori Natsuki, Kumon Masanobu, Nishiyama Yuya, Adachi Kazuhide, Nagahisa Shinya, Hayashi Takuro, Inamasu Joji, Abe Masato, Hasegawa Mitsuhiro, Hirose Yuic |
|
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Acta neuropathologica communications 2015 3 (1): 88. Draaisma Kaspar, Wijnenga Maarten M J, Weenink Bas, Gao Ya, Smid Marcel, Robe P, van den Bent Martin J, French Pim |
|
TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
International journal of clinical and experimental pathology 2015 8 (9): 11485-94. Sun Ze-Lin, Chan Aden Ka-Yin, Chen Ling-Chao, Tang Chao, Zhang Zhen-Yu, Ding Xiao-Jie, Wang Yang, Sun Chong-Ran, Ng Ho-Keung, Yao Yu, Zhou Liang- |
|
Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Neuro-oncology 2014 Dec 16 (12): 1607-17. Jha Prerana, Pia Patric Irene Rosita, Shukla Sudhanshu, Pathak Pankaj, Pal Jagriti, Sharma Vikas, Thinagararanjan Sivaarumugam, Santosh Vani, Suri Vaishali, Sharma Mehar Chand, Arivazhagan Arimappamagan, Suri Ashish, Gupta Deepak, Somasundaram Kumaravel, Sarkar Chit |
|
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
Neuro-oncology 2014 Nov 16 (11): 1478-83. Chen Li, Voronovich Zoya, Clark Kenneth, Hands Isaac, Mannas Jonathan, Walsh Meggen, Nikiforova Marina N, Durbin Eric B, Weiss Heidi, Horbinski Cra |
|
[IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
Zhonghua bing li xue za zhi Chinese journal of pathology 2014 Oct 43 (10): 668-72. Jiang Mengwan, Dong Xianghui, Li Jiayao, Li Jingqi, Qi Jipi |
|
KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014 Oct 21 (10): 1719-24. Gousias Konstantinos, Niehusmann Pitt, Gielen Gerrit, Simon Matthias, Boström J |
|
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Journal of neuro-oncology 2014 Oct 120 (1): 85-93. Kizilbash Sani H, Giannini Caterina, Voss Jesse S, Decker Paul A, Jenkins Robert B, Hardie John, Laack Nadia N, Parney Ian F, Uhm Joon H, Buckner Jan |
|
IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
Epilepsia 2014 Sep 55 (9): 1438-43. Liubinas Simon V, D'Abaco Giovanna M, Moffat Bradford M, Gonzales Michael, Feleppa Frank, Nowell Cameron J, Gorelik Alexandra, Drummond Katharine J, O'Brien Terence J, Kaye Andrew H, Morokoff Andrew |
|
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
Neuro-oncology 2014 Sep 16 (9): 1263-73. Molenaar Remco J, Verbaan Dagmar, Lamba Simona, Zanon Carlo, Jeuken Judith W M, Boots-Sprenger Sandra H E, Wesseling Pieter, Hulsebos Theo J M, Troost Dirk, van Tilborg Angela A, Leenstra Sieger, Vandertop W Peter, Bardelli Alberto, van Noorden Cornelis J F, Bleeker Fonnet |
|
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Journal of neuro-oncology 2014 Jun 118 (2): 377-83. Minniti Giuseppe, Scaringi Claudia, Arcella Antonella, Lanzetta Gaetano, Di Stefano Domenica, Scarpino Stefania, Bozzao Alessandro, Pace Andrea, Villani Veronica, Salvati Maurizio, Esposito Vincenzo, Giangaspero Felice, Enrici Riccardo Mauri |
|
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Jun 20 (11): 2898-909. Wakimoto Hiroaki, Tanaka Shota, Curry William T, Loebel Franziska, Zhao Dan, Tateishi Kensuke, Chen Juxiang, Klofas Lindsay K, Lelic Nina, Kim James C, Dias-Santagata Dora, Ellisen Leif W, Borger Darrell R, Fendt Sarah-Maria, Vander Heiden Matthew G, Batchelor Tracy T, Iafrate A John, Cahill Daniel P, Chi Andrew |
|
Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.
AJNR. American journal of neuroradiology 2014 May 35 (5): 920-7. Tan W L, Huang W Y, Yin B, Xiong J, Wu J S, Geng D |
|
Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.
Journal of cancer research and clinical oncology 2014 Jan 140 (1): 45-51. Zhang Chuan-Bao, Bao Zhao-Shi, Wang Hong-Jun, Yan Wei, Liu Yan-Wei, Li Ming-Yang, Zhang Wei, Chen Ling, Jiang T |
|
IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
BioMed research international 2014 2014 654727. Stancheva Gergana, Goranova Teodora, Laleva Maria, Kamenova Margarita, Mitkova Atanaska, Velinov Nikolay, Poptodorov George, Mitev Vanio, Kaneva Radka, Gabrovsky Nikol |
|
Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
BioMed research international 2014 2014 735659. Polivka J, Polivka J, Rohan V, Pesta M, Repik T, Pitule P, Topolcan |
|
Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Asian Pacific journal of cancer prevention : APJCP 2014 15 (24): 10893-8. Wang Kai, Wang Yin-Yan, Ma Jun, Wang Jiang-Fei, Li Shao-Wu, Jiang Tao, Dai Jian-Pi |
|
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Acta neuropathologica 2013 Dec 126 (6): 907-15. Koelsche Christian, Sahm Felix, Capper David, Reuss David, Sturm Dominik, Jones David T W, Kool Marcel, Northcott Paul A, Wiestler Benedikt, Böhmer Katja, Meyer Jochen, Mawrin Christian, Hartmann Christian, Mittelbronn Michel, Platten Michael, Brokinkel Benjamin, Seiz Marcel, Herold-Mende Christel, Unterberg Andreas, Schittenhelm Jens, Weller Michael, Pfister Stefan, Wick Wolfgang, Korshunov Andrey, von Deimling Andre |
|
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Neuro-oncology 2013 Dec . Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP |
|
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013 Dec 34 (6): 3555-9. Cheng Hong-Bin, Yue Wu, Xie Chen, Zhang Ru-You, Hu Shao-Shan, Wang Z |
|
Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
Neuro-oncology 2013 Dec 15 (12): 1635-43. Laxton Ross C, Popov Sergey, Doey Lawrence, Jury Alexa, Bhangoo Ranj, Gullan Richard, Chandler Chris, Brazil Lucy, Sadler Gill, Beaney Ron, Sibtain Naomi, King Andrew, Bodi Istvan, Jones Chris, Ashkan Keyoumars, Al-Sarraj Sa |
|
TERT promoter mutations in primary and secondary glioblastomas.
Acta neuropathologica 2013 Dec 126 (6): 931-7. Nonoguchi Naosuke, Ohta Takashi, Oh Ji-Eun, Kim Young-Ho, Kleihues Paul, Ohgaki Hiro |
|
Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Sep 19 (18): 5146-57. Hartmann Christian, Hentschel Bettina, Simon Matthias, Westphal Manfred, Schackert Gabriele, Tonn Jörg C, Loeffler Markus, Reifenberger Guido, Pietsch Torsten, von Deimling Andreas, Weller Michael, |
|
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Journal of neuro-oncology 2013 Aug 114 (1): 85-91. Frenel J S, Leux C, Loussouarn D, Le Loupp A-G, Leclair F, Aumont M, Mervoyer A, Martin S, Denis M G, Campone |
|
Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013 Jul 26 (7): 922-9. Boots-Sprenger Sandra H E, Sijben Angelique, Rijntjes Jos, Tops Bastiaan B J, Idema Albert J, Rivera Andreana L, Bleeker Fonnet E, Gijtenbeek Anja M, Diefes Kristin, Heathcock Lindsey, Aldape Kenneth D, Jeuken Judith W M, Wesseling Piet |
|
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Oncogene 2013 Jun 32 (25): 3091-100. Wang P, Dong Q, Zhang C, Kuan P-F, Liu Y, Jeck W R, Andersen J B, Jiang W, Savich G L, Tan T-X, Auman J T, Hoskins J M, Misher A D, Moser C D, Yourstone S M, Kim J W, Cibulskis K, Getz G, Hunt H V, Thorgeirsson S S, Roberts L R, Ye D, Guan K-L, Xiong Y, Qin L-X, Chiang D |
|
Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.
Journal of neuro-oncology 2013 May 112 (3): 439-48. Ha Sang Yun, Kang So Young, Do In-Gu, Suh Yeon-L |
|
[Correlation between IDH1 mutation and prognosis in supratentorial high-grade astrocytomas].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 2013 Mar 44 (2): 184-7, 192. Xie Fei, Tang Jun-Jia, Wang Xiang, Liu Yan-Hui, Mao Qi |
|
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Neuro-oncology 2013 Mar . Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S |
|
Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients.
Journal of molecular neuroscience : MN 2013 Mar 49 (3): 567-73. Hilmani Said, Abidi Omar, Benrahma Houda, Karkouri Mehdi, Sahraoui Souha, El Azhari Abdessamad, Barakat Abdelham |
|
Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.
Journal of neuro-oncology 2013 Mar . Zhang GB, Cui XL, Sui DL, Ren XH, Zhang Z, Wang ZC, Lin S |
|
Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
Neuro-oncology 2013 Feb . Rice T, Zheng S, Decker PA, Walsh KM, Bracci P, Xiao Y, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, Chang SM, Berger MS, Caron A, Fink S, Kollmeyer T, Rynearson A, Voss J, Kosel ML, Fridley BL, Lachance DH, Eckel-Passow JE, Sicotte H, O'Neill BP, Giannini C, Wiencke JK, Jenkins RB, Wrensch MR |
|
[Relationship between IDH1 mutation and clinic pathologic features in human supratentorial WHO grade II gliomas].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 2013 Jan 44 (1): 60-3. Tang Jun-Jia, Xie Fei, Wang Xiang, Zhang Dou-Dou, Liu Shuang, Liu Yan-Hui, Mao Qi |
|
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
PloS one 2013 8 (6): e67139. Kuo Lu-Ting, Tsai Shao-Yu, Chang Cheng-Chi, Kuo Kuang-Ting, Huang Abel Po-Hao, Tsai Jui-Chang, Tseng Ham-Min, Kuo Meng-Fai, Tu Yong-Kwa |
|
Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
Journal of experimental & clinical cancer research : CR 2013 32 (1): 59. Wang Zheng, Bao Zhaoshi, Yan Wei, You Gan, Wang Yinyan, Li Xuejun, Zhang W |
|
Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Asian Pacific journal of cancer prevention : APJCP 2013 14 (12): 7261-4. Das Bibhu Ranjan, Tangri Rajiv, Ahmad Firoz, Roy Arnab, Patole Kamlak |
|
Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
PloS one 2013 8 (6): e67421. Yao Yu, Chan Aden Ka-Yin, Qin Zhi Yong, Chen Ling Chao, Zhang Xin, Pang Jesse Chung-Sean, Li Hiu Ming, Wang Yin, Mao Ying, Ng Ho-Keung, Zhou Liang |
|
Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
World journal of surgical oncology 2013 11 (1): 284. Takahashi Yoshinobu, Nakamura Hideo, Makino Keishi, Hide Takuichiro, Muta Daisuke, Kamada Hajime, Kuratsu Jun-Ic |
|
Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.
BioMed research international 2013 2013 756302. Mellai Marta, Piazzi Angela, Caldera Valentina, Annovazzi Laura, Monzeglio Oriana, Senetta Rebecca, Cassoni Paola, Schiffer Davi |
|
Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.
PloS one 2013 8 (6): e65444. Bie?kowski Micha?, Piaskowski Sylwester, Stoczy?ska-Fidelus Ewelina, Szybka Ma?gorzata, Banaszczyk Mateusz, Witusik-Perkowska Monika, Jesie?-Lewandowicz Emilia, Jaskólski Dariusz J, Radomiak-Za?uska Anna, Jesionek-Kupnicka Dorota, Sikorska Beata, Papierz Wielis?aw, Rieske Piotr, Liberski Pawe? |
|
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
International journal of clinical oncology 2012 Dec 17 (6): 551-61. Shibahara Ichiyo, Sonoda Yukihiko, Kanamori Masayuki, Saito Ryuta, Yamashita Yoji, Kumabe Toshihiro, Watanabe Mika, Suzuki Hiroyoshi, Kato Shunsuke, Ishioka Chikashi, Tominaga Tei |
|
The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Journal of neuro-oncology 2012 Dec 110 (3): 325-33. Juratli T A, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schrok E, Schackert G, Krex |
|
IDH1 mutation of gliomas with long-term survival analysis.
Oncology reports 2012 Nov 28 (5): 1639-44. Myung Jae Kyung, Cho Hwa Jin, Park Chul-Kee, Kim Seung-Ki, Phi Ji Hoon, Park Sung-H |
|
IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
Fetal and pediatric pathology 2012 Oct 31 (5): 278-82. Buccoliero Anna Maria, Castiglione Francesca, Degl'Innocenti Duccio Rossi, Gheri Chiara Francesca, Genitori Lorenzo, Taddei Gian Lui |
|
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
International journal of oncology 2012 Sep 41 (3): 1029-35. Lv Shasha, Teugels Erik, Sadones Jan, De Brakeleer Sylvia, Duerinck Johnny, Du Four Stephanie, Michotte Alex, De Grève Jacques, Neyns Ba |
|
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
International journal of cancer. Journal international du cancer 2012 Aug 131 (3): 766-8. Capper David, Simon Matthias, Langhans Claus-Dieter, Okun Jürgen G, Tonn Jörg C, Weller Michael, von Deimling Andreas, Hartmann Christian, |
|
IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
American journal of clinical pathology 2012 Aug 138 (2): 177-84. Thota Balaram, Shukla Sudhanshu K, Srividya Mallavarapu R, Shwetha Shivayogi D, Arivazhagan Arimappamagan, Thennarasu Kandavel, Chickabasaviah Yasha T, Hegde Alangar S, Chandramouli Bangalore A, Somasundaram Kumarvel, Santosh Va |
|
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Journal of neuro-oncology 2012 Aug 109 (1): 15-22. Ahmadi Rezvan, Stockhammer Florian, Becker Natalia, Hohlen Katarina, Misch Martin, Christians Arne, Dictus Christine, Herold-Mende Christel, Capper David, Unterberg Andreas, von Deimling Andreas, Wick Wolfgang, Hartmann Christi |
|
IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
Journal of neuro-oncology 2012 Jul 108 (3): 403-10. Juratli Tareq A, Kirsch Matthias, Robel Katja, Soucek Silke, Geiger Kathrin, von Kummer Rüdiger, Schackert Gabriele, Krex Dietm |
|
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.
Journal of neuro-oncology 2012 May 108 (1): 69-75. Gozé Catherine, Bezzina Charlotte, Gozé Eric, Rigau Valérie, Maudelonde Thierry, Bauchet Luc, Duffau Hugu |
|
IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
Seizure 2012 Apr 21 (3): 194-7. Stockhammer Florian, Misch Martin, Helms Hans-Joachim, Lengler Ulrike, Prall Friedrich, von Deimling Andreas, Hartmann Christi |
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 13, 2019
- Content source: